Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

NYSE:DNA   3:59:59 PM EDT
5.80
-0.34 (-5.54%)
: $5.69 -0.11 (-1.90%)
Products

Selecta Biosciences And Ginkgo Bioworks Announce New Collaboration To Develop Next-Gen Gene Therapy Capsids

Published: 01/10/2022 12:13 GMT
Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A (DNA) - Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-generation Gene Therapy Capsids.
Ginkgo Bioworks - Eligible to Earn Upfront Research and Development Fees and Milestone Payments, Including Certain Payments in Form of Selecta Stock.
Ginkgo Bioworks - Eligible to Earn Clinical, Regulatory & Commercial Milestone Payments of Up to $200 Million for Each of Specified Number of Products.
Ginkgo Bioworks Holdings Inc - is Also Entitled to Potential Further Downstream Value in Form of Royalties on Sales.
Ginkgo Bioworks - Clinical, Regulatory and Commercial Milestone Payments Have Potential to Total Up to $1.1 Billion.